Project goal

Nanotechnology is one of the key enabling technologies for the development of innovative and disruptive medical technologies. In the face of rising worldwide healthcare costs there is great demand for such new technologies, which needs to be carefully balanced against potential risks. The safety evaluation and risk assessment of nano-enabled medical technologies presents a particular challenge, as the unique physicochemical properties of nano materials can give rise to unwanted biological interactions, and standardized characterization methods are often lacking. 

SAFE-N-MEDTECH will build an innovative open access platform for companies and reference laboratories in the nano-enabled medical technology space – the Open Innovation Test Bed (OITB). The project partners will work together to develop and share the capabilities, know-how, networks and services required for nanotechnology-based Medical and Diagnostic Devices across their entire life cycle - from their development, testing, and assessment, to upscaling and market exploitation.


VITO is technical leading partner for diagnostic test case provider Helia Biomonitoring, a spin-off company of the Technical University of Eindhoven. In this role, VITO will provide its nano-biotechnology expertise for assay development on Helia’s particle mobility-based biosensing platform for continuous monitoring of biomarkers.



European Union's Horizon 2020 Programmes 
H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials 
H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies 
Grant agreement n° 814607
April 2019 – March 2023


Website Safe-N-Medtech

Consortium partners

Inge Nelissen

+32 14 33 52 11